A5012829870- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Gastric Cancer Management and Outcomes
- Lung Cancer Research Studies
- Gastrointestinal Tumor Research and Treatment
- Brain Metastases and Treatment
- Ferroptosis and cancer prognosis
- Cancer Genomics and Diagnostics
- Esophageal Cancer Research and Treatment
- Lymphoma Diagnosis and Treatment
- Viral-associated cancers and disorders
- Metastasis and carcinoma case studies
- Bariatric Surgery and Outcomes
- Tissue Engineering and Regenerative Medicine
- Glioma Diagnosis and Treatment
- Respiratory and Cough-Related Research
- Drug-Induced Adverse Reactions
- Colorectal Cancer Treatments and Studies
- Lung Cancer Diagnosis and Treatment
- Cancer Diagnosis and Treatment
- Inflammasome and immune disorders
- Organ Transplantation Techniques and Outcomes
- Dermatologic Treatments and Research
- Laser Applications in Dentistry and Medicine
- SARS-CoV-2 detection and testing
Beijing Jishuitan Hospital
2019-2024
Guangdong Provincial People's Hospital
2019-2024
Guangdong Academy of Medical Sciences
2018-2024
Southern Medical University
2004-2024
Capital Medical University
2024
Peking University
2019-2024
Second Military Medical University
2021-2024
Guilin Medical University
2022
Tongren Hospital
2022
Shanghai Jiao Tong University
2022
The efficacy and potential limitations of molecular residual disease (MRD) detection urgently need to be fully elucidated in a larger population non-small cell lung cancer (NSCLC). We enrolled 261 patients with stages I III NSCLC who underwent definitive surgery, 913 peripheral blood samples were successfully detected by MRD assay. Within the population, only six (3.2%) longitudinal undetectable recurred, resulting negative predictive value 96.8%. Longitudinal may define cured. peak risk...
Serum samples from 317 patients with severe acute respiratory syndrome (SARS) were tested for the nucleocapsid (N) protein of SARS-associated coronavirus, sensitivities 94% and 78% first 5 days 6-10 after onset, respectively. The specificity was 99.9%. N can be used as an early diagnostic maker SARS.
Multiple primary lung cancer (MPLC) remains a tough challenge to diagnose and treat. Although neoadjuvant immunotherapy has shown promising results in early stage non-small cell cancer, whether such modality can benefit all lesions unclear. Herein, we performed integrated multiomics analysis one patient with MPLC remarkable tumor shrinkage solid nodule no response two subsolid nodules after treatment three cycles of pembrolizumab. Genomic heterogeneity was observed among responding high...
Leptomeningeal metastases (LMs) remain a devastating complication of non-small cell lung cancer (NSCLC), particularly following osimertinib resistance. We conducted single-cell RNA sequencing on cerebrospinal fluid (CSF) from EGFR-mutant NSCLC with central nervous system metastases. found that macrophages LMs displayed functional and phenotypic heterogeneity enhanced immunosuppressive properties. A population lipid-associated macrophages, namely RNASE1_M, were linked to resistance LM...
The diagnosis of invasive aspergillosis (IA) based on the detection Aspergillus galactomannan (GM) is complicated by presence cross-reactive GM epitopes in patient specimens. We have developed a novel and specific antigen-capture enzyme-linked immunosorbent assay (ELISA) selection two well-characterized monoclonal antibodies from 17 candidate antibodies. recognized were present cell walls hyphae conidia species, which circulating or excreted as immunodominant antigens during acute phase IA...
Primary pulmonary lymphoepithelioma-like carcinoma (PLELC) is a rare and unique subtype of lung cancer. However, the prevalence driver alterations, such as epidermal growth factor receptor (EGFR) mutations anaplastic lymphoma kinase (ALK) rearrangements, response tyrosine inhibitor (TKIs) in PLELC has not been thoroughly investigated.We retrospectively reviewed genetic profiles treatment course 330 patients at Guangdong Lung Cancer Institute (GLCI) from 1st January, 2008 to 30th December,...
Despite the reported efficacy of osimertinib, central nervous system (CNS) progression is still frequent in EGFR-mutated NSCLC. This study aimed to reveal site-specific resistant mechanisms osimertinib and investigate subsequent treatments for leptomeningeal metastases (LM).EGFR-mutated NSCLC with LM who progressed on were included. Molecular analysis cerebrospinal fluid (CSF) at was performed. Subsequent collected analyzed.A total 246 patients identified. Only those as a site included...
Primary pulmonary lymphoepithelioma-like carcinoma (PLELC) is an Epstein–Barr virus (EBV)-related, rare subtype of non-small-cell lung cancer (NSCLC). Immune checkpoint inhibitors (ICI) show durable responses in advanced NSCLC. However, their effects and predictive biomarkers PLELC remain poorly understood. We retrospectively analyzed the data 48 metastatic patients treated with ICI. Pretreated paraffin-embedded specimens (n = 19) were stained for PD-1, PD-L1, LAG3, TIM3, CD3, CD4, CD8,...
Abstract Background Brain metastases (BM) are common in lung cancer. However, data on the status of immune biomarkers BM lesions remain limited. Methods We retrospectively analyzed PD‐L1 expression and infiltration levels CD3 + , CD4 CD8 T cells as by immunohistochemistry both primary cancer (PL) 29 (LC) patients. In addition, correlations between these clinical outcome were using log‐rank test. Results Intratumoral heterogeneous was observed tumor (TCs) 11 cases (ICs) 10 with samples from...
MET inhibitors have shown promising efficacy for MET-dysregulated non-small cell lung cancer (NSCLC). However, quite a few patients cannot benefit from it due to the lack of powerful biomarkers. This study aims explore potential role plasma proteomics-derived biomarkers treated with using mass spectrometry. We analyzed proteomics dysregulation (including amplification and overexpression) inhibitors. Thirty-three NSCLC longitudinal 89 samples were included. classified into PD group non-PD...
Treatment by immune checkpoint blockade (ICB) provides a remarkable survival benefit for multiple cancer types. However, disease aggravation occurs in proportion of patients after the first couple treatment cycles.RNA sequencing data was retrospectively collected. 6 tumour-immune related features were extracted and combined to build lung cancer-specific predictive model distinguish responses as progression (PD) or non-PD. This trained 3 public pan-cancer datasets cohort from our institute,...
Breast cancer (BC) is the most common affecting women and leading cause of cancer-related deaths worldwide. Compelling evidence indicates that pyroptosis inextricably involved in development may activate tumor-specific immunity and/or enhance effectiveness existing therapies. We constructed a novel prognostic prediction model for BC, based on pyroptosis-related clusters, according to RNA-seq clinical data downloaded from TCGA. The proportions tumor-infiltrating immune cells differed...
The optimal proximal margin (PM) length for Siewert II/III adenocarcinoma of the esophagogastric junction (AEJ) remains unclear. This study aimed to determine PM using an abdominal approach guide surgical decision-making. A prospective analyzed 304 consecutive patients diagnosed with AEJ between January 2019 and December 2021. Total gastrectomy was performed via approach, measured on fixed gross specimens. X-Tile software determined cut-point based progression-free survival (PFS). Univariate...
OBJECTIVE: To evaluate the impact of different techniques for gastrointestinal tract reconstruction on postoperative pancreatic β-cell function in patients with type 2 diabetes mellitus (T2DM). METHODS: Twenty-three gastric cancer and T2DM were studied. Techniques included Billroth I (n=13) bypass procedures(Billroth II n=4 Roux-en-Y anastomosis n=6). Pancreatic was evaluated by oral glucose tolerance test (OGTT). Serum insulin measured electrochemiluminescence immunoassay blood oxidase...
The efficacy of immunotherapy in advanced HER2-mutated non-small-cell lung cancer (NSCLC) remains incomprehensively studied. A total 107 NSCLC patients with de novo HER2 mutations were retrospectively studied at Guangdong Lung Cancer Institute [GLCI cohort, exon 20 insertions (ex20ins): 71.0%] to compare clinical/molecular features and immune checkpoint inhibitor (ICI)-based therapy between ex20ins non-ex20ins. Two external cohorts (TCGA, n = 21; META-ICI, 30) used for validation. In the...